GlassScriptPhysician profile
John M Coleman
NPI 1396900791
$10,769.17
in general payments reported to CMS, 2019-2025
10 companies · $7,771 in 2025
The $7,771 reported for 2025 was more than what 95% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2021: $720 · 2022: $1,170 · 2023: $926 · 2025: $7,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,296 · Food and Beverage: $347 · Travel and Lodging: $54.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,295.60 |
| Food and Beverage | $347.43 |
| Travel and Lodging | $54.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $4,221.95 | 2025 | Hillrom - Volara System |
| Resmed Corp | $3,640.20 | 2022-2025 | |
| 3b Medical, INC. | $1,170.51 | 2025 | Luna |
| Fisher & Paykel Healthcare Limited | $700.00 | 2025 | Fisher & Paykel Healthcare |
| Advanced Respiratory, INC | $406.96 | 2019-2021 | |
| Hill-Rom Services, INC | $360.00 | 2021 | |
| Biogen, INC. | $118.03 | 2025 | Qalsody |
| Genzyme Corporation | $96.13 | 2019 | |
| Hill-Rom Company, INC | $38.95 | 2019 | |
| Glaxosmithkline, LLC. | $16.44 | 2023 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.